Logo image of AAPG

ASCENTAGE PHARMA GR-ADR (AAPG) Stock Fundamental Analysis

NASDAQ:AAPG - Nasdaq - ADR - Currency: USD

40.39  +0.77 (+1.94%)

After market: 40 -0.39 (-0.97%)

Fundamental Rating

3

Taking everything into account, AAPG scores 3 out of 10 in our fundamental rating. AAPG was compared to 558 industry peers in the Biotechnology industry. AAPG may be in some trouble as it scores bad on both profitability and health. AAPG shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AAPG has reported negative net income.
In the past year AAPG has reported a negative cash flow from operations.
AAPG had negative earnings in each of the past 5 years.
AAPG had a negative operating cash flow in each of the past 5 years.
AAPG Yearly Net Income VS EBIT VS OCF VS FCFAAPG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500M -1B

1.2 Ratios

The Return On Assets of AAPG (-15.49%) is better than 80.65% of its industry peers.
The Return On Equity of AAPG (-153.46%) is worse than 62.19% of its industry peers.
Industry RankSector Rank
ROA -15.49%
ROE -153.46%
ROIC N/A
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
AAPG Yearly ROA, ROE, ROICAAPG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 97.03%, AAPG belongs to the top of the industry, outperforming 97.31% of the companies in the same industry.
In the last couple of years the Gross Margin of AAPG has grown nicely.
The Profit Margin and Operating Margin are not available for AAPG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
AAPG Yearly Profit, Operating, Gross MarginsAAPG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

AAPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
AAPG has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AAPG has been increased compared to 5 years ago.
The debt/assets ratio for AAPG has been reduced compared to a year ago.
AAPG Yearly Shares OutstandingAAPG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AAPG Yearly Total Debt VS Total AssetsAAPG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

AAPG has an Altman-Z score of 3.07. This indicates that AAPG is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.07, AAPG is doing good in the industry, outperforming 73.84% of the companies in the same industry.
A Debt/Equity ratio of 4.46 is on the high side and indicates that AAPG has dependencies on debt financing.
The Debt to Equity ratio of AAPG (4.46) is worse than 82.97% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.46
Debt/FCF N/A
Altman-Z 3.07
ROIC/WACCN/A
WACC7.76%
AAPG Yearly LT Debt VS Equity VS FCFAAPG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

A Current Ratio of 1.26 indicates that AAPG should not have too much problems paying its short term obligations.
AAPG has a worse Current ratio (1.26) than 84.23% of its industry peers.
A Quick Ratio of 1.26 indicates that AAPG should not have too much problems paying its short term obligations.
AAPG's Quick ratio of 1.26 is on the low side compared to the rest of the industry. AAPG is outperformed by 83.33% of its industry peers.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.26
AAPG Yearly Current Assets VS Current LiabilitesAAPG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 61.43% over the past year.
AAPG shows a strong growth in Revenue. In the last year, the Revenue has grown by 341.77%.
AAPG shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 132.25% yearly.
EPS 1Y (TTM)61.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.86%
Revenue 1Y (TTM)341.77%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%97.9%

3.2 Future

Based on estimates for the next years, AAPG will show a very strong growth in Earnings Per Share. The EPS will grow by 24.96% on average per year.
The Revenue is expected to grow by 23.37% on average over the next years. This is a very strong growth
EPS Next Y-182.73%
EPS Next 2Y103.09%
EPS Next 3Y24.96%
EPS Next 5YN/A
Revenue Next Year-48.7%
Revenue Next 2Y58.4%
Revenue Next 3Y17.2%
Revenue Next 5Y23.37%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AAPG Yearly Revenue VS EstimatesAAPG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
AAPG Yearly EPS VS EstimatesAAPG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AAPG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AAPG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AAPG Price Earnings VS Forward Price EarningsAAPG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AAPG Per share dataAAPG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as AAPG's earnings are expected to grow with 24.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y103.09%
EPS Next 3Y24.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AAPG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASCENTAGE PHARMA GR-ADR

NASDAQ:AAPG (7/18/2025, 8:27:52 PM)

After market: 40 -0.39 (-0.97%)

40.39

+0.77 (+1.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/bmo
Earnings (Next)N/A N/A
Inst Owners8.36%
Inst Owner Change0%
Ins Owners13.63%
Ins Owner ChangeN/A
Market Cap3.52B
Analysts86.15
Price Target34.93 (-13.52%)
Short Float %0.02%
Short Ratio1.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)37.39%
PT rev (3m)47.95%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-3.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.77
P/FCF N/A
P/OCF N/A
P/B 95.64
P/tB 154.55
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-1.55
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS1.57
BVpS0.42
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.49%
ROE -153.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.03%
FCFM N/A
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 4.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.07%
Cap/Sales 2.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.26
Quick Ratio 1.26
Altman-Z 3.07
F-Score5
WACC7.76%
ROIC/WACCN/A
Cap/Depr(3y)161.69%
Cap/Depr(5y)588.72%
Cap/Sales(3y)47.03%
Cap/Sales(5y)745.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.86%
EPS Next Y-182.73%
EPS Next 2Y103.09%
EPS Next 3Y24.96%
EPS Next 5YN/A
Revenue 1Y (TTM)341.77%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%97.9%
Revenue Next Year-48.7%
Revenue Next 2Y58.4%
Revenue Next 3Y17.2%
Revenue Next 5Y23.37%
EBIT growth 1Y57.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-259.46%
EBIT Next 3Y26%
EBIT Next 5YN/A
FCF growth 1Y82.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y84.66%
OCF growth 3YN/A
OCF growth 5YN/A